Amphotericin B formulations and other drugs for visceral leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 92, Issue 3, 2015, Pages 471-473

  Berman, Jonathan ^a  

^a Fast Track Drugs and Biologies LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; MILTEFOSINE; PAROMOMYCIN; ANTIPROTOZOAL AGENT; DRUG DOSAGE FORM;

CHILL; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; EDITORIAL; FEVER; HUMAN; INCIDENCE; INDIAN; INFUSION RELATED REACTION; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LUNG EDEMA; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); THROMBOCYTOPENIA; VISCERAL LEISHMANIASIS; VOMITING; CHEMISTRY; DRUG DOSAGE FORM; LEISHMANIASIS, VISCERAL;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DOSAGE FORMS; HUMANS; LEISHMANIASIS, VISCERAL;

EID: 84924246990     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0743     Document Type: Editorial

References (20)

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; Leishmaniasis Control Team WHO, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7: e35671.
2. Sundar S, 2001. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854.
3. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
4. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581.
5. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377-383.
6. Ambisome label. 2000. Available at: http://www.accessdata.fda .gov/drugsatfda-docs/nda/2000/50-740S001-AmBisome-prntlbl.pdf. AccessedDecember 10, 2014.
7. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R, 2002. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66: 143-146.
8. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800-804.
9. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512.
10. Sundar S, Mehta H, Chhabra A, Singh V, Chauhan V, Desjeux P, Rai M, 2006. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 42: 608-613.
11. Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P, 2014. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. PLoS Negl Trop Dis 8: e3169.
12. Sundar S, Singh A, Rai M, Chakravarty J, 2015. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. Am J Trop Med Hyg 92: 513-517.
13. Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B, 2014. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health 2: e51-e57.
14. Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J, 2009. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs. 21-day treatment. Clin Infect Dis 49: 914-918.
15. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J, 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543-550.
16. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an openlabel, non-inferiority, randomized controlled trial. Lancet 377: 477-486.
17. Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A, 2014. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomized trial. PLoS Negl Trop Dis 8: e2613.
18. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD, 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 22: 938-943.
19. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J; Leishmaniasis East Africa Platform (LEAP) group, 2010. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 4: e709.
20. Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G, 2003. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 36: 560-566.